Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 10/20 | 0.60 |
| ▸ | STAT3 | P40763 | 8/20 | 0.46 |
| ▸ | GIPR | P48546 | 6/20 | 0.42 |
| ▸ | GLP1R | P43220 | 1/20 | 0.42 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2652974 | 0.90 | GCGR (0.71) | GCGRSTAT3GIPRGLP1R | |
| SCHEMBL4095401 | 0.90 | GCGR (0.71) | GCGRSTAT3GIPRGLP1R | |
| Beta-Alanine SCHEMBL6494757 | 0.88 | GCGR (0.51) | GCGRSTAT3SERPINE1NR1H4 | |
| SCHEMBL2653512 | 0.83 | GCGR (0.68) | GCGRSTAT3GIPRGLP1R | |
| SCHEMBL2655374 | 0.81 | GCGR (0.80) | GCGRGIPRGLP1R | |
| SCHEMBL2654610 | 0.80 | GCGR (0.66) | GCGRSTAT3GIPRGLP1R | |
| SCHEMBL2651179 | 0.79 | GCGR (0.83) | GCGRGIPRGLP1R | |
| SCHEMBL2654233 | 0.79 | GCGR (0.58) | GCGRSTAT3GIPRGLP1R | |
| SCHEMBL2656083 | 0.77 | GCGR (0.59) | GCGRSTAT3GIPRGLP1R | |
| SCHEMBL2654511 | 0.77 | GCGR (0.62) | GCGRGIPRGLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050203108-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203108-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | GCGR 3/4885STAT3 1079/4885GIPR 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.